| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Operating Officer | Director
1 company
Tony Goodman is Chief Operating Officer at ADIL. Tony Goodman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $134K at current prices.
Net of sales, the ADIL filings show accumulation of 7,000 shares.
Tony Goodman has 9 Form 4 filings on record from July 2018 to April 2026, all as Chief Operating Officer at Adial Pharmaceuticals (ADIL), 2018–2026.
The 10 reported transactions were 7 option or other derivative awards, 2 open-market purchases and 1 stock award.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 31, 2018 | ADIL Adial Pharmaceuticals, Inc. | Director | Buy | 7,000 | $0.00 | - | +398.9% |